Galera to Present at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting

MALVERN, Pa., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that tumor outcomes data from its Phase 3 ROMAN trial of avasopasem for severe oral mucositis (SOM) and final data from its Phase 2 AESOP trial of avasopasem for chemoradiotherapy-induced esophagitis will be highlighted in two presentations at the upcoming 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting, taking place October 23-26, 2022 in San Antonio, Texas. Additionally, poster presentations will highlight the Phase 2 EUSOM trial of avasopasem for SOM in Europe and the ongoing GRECO-1 trial of rucosopasem for non-small cell lung cancer.

Presentation Details

Title: Tumor Outcomes for ROMAN: Phase 3 Trial of Avasopasem Manganese (GC4419) for Severe Oral
Mucositis (SOM) in Patients Receiving Chemoradiotherapy (CRT) for Locally Advanced Head and Neck Cancer (LAHNC)
Abstract Number: 280
Presenter: Carryn M. Anderson, M.D., University of Iowa Hospitals & Clinics
Session Title: H&N 3 - Toxicity Mitigation and HPV-Unrelated Head and Neck Cancer - Life Beyond De-Intensification
Session Date and Time: Wednesday, October 26, 2022 | 12:40 p.m. CDT
Session Location: Henry B. Gonzalez Convention Center, Room 214

Title: AESOP: Phase 2 Open-Label Trial of Avasopasem Manganese (GC4419) for Reduction of Esophagitis in Patients Receiving Chemoradiotherapy for Nonmetastatic Lung Cancer
Abstract Number: 1124
Presenter: Bryan G. Allen, M.D., Ph.D., University of Iowa Hospitals & Clinics
Session Title: Lung 3 - Optimizing Radiation Dose, Volume, and Concomitant Systemic Agents
Session Date and Time: Wednesday, October 26, 2022 | 10:50 a.m. CDT
Session Location: Henry B. Gonzalez Convention Center, Room 303